Use of CD36 to identify cancer subjects for treatment
Provided herein are methods for identifying a subject with cancer for treatment with a Psap peptides. The subject is identified based on a level of CD36. Also provided herein are compositions and methods for treatment of a subject with cancer based on a level of CD36.
1. A method for treating cancer in a subject in need thereof, the method comprising: administering to the subject an effective amount of a prosaposin (Psap) peptide, wherein the cancer is characterized by an elevated level of CD36 as compared to a control level of CD36, and wherein the Psap peptide consists of a sequence selected from the group consisting of CDWLPK (SEQ ID NO: 1), DWLPK (SEQ ID NO: 2), and DWLP (SEQ ID NO: 3).
2. The method of claim 1 , wherein the control level is a level of CD36 in a cell or tissue obtained from a healthy subject or a population of healthy subjects.
3. The method of claim 1 , wherein the control level is a predetermined level.
4. The method of claim 1 , wherein the level of CD36 is a CD36 protein level.
5. The method of claim 1 , wherein the cancer is prostate cancer, breast cancer, ovarian cancer, lung cancer, leukemia, pancreatic cancer, glioblastoma multiforme, astrocytoma, or melanoma.
6. The method of claim 1 , wherein the Psap peptide is a cyclic peptide.
7. The method of claim 1 , wherein the control level is a level of CD36 from a non-cancerous cell or tissue obtained from the subject having the cancer.
8. The method of claim 1 , wherein the Psap peptide comprises one or more modifications selected from the group consisting of acetylation, pegylation, and conjugation to a non-peptide polymer that enhances serum half-life of the peptide.
9. The method of claim 1 , wherein the Psap peptide is a dimer, trimer, or multimer.